Zacks Investment Research Upgrades NantHealth Inc (NH) to “Hold”
NantHealth Inc (NYSE:NH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “
NH has been the topic of a number of other reports. First Analysis assumed coverage on NantHealth in a report on Monday, June 27th. They set an “overweight” rating and a $18.00 price objective on the stock. FBR & Co reissued a “buy” rating on shares of NantHealth in a report on Wednesday, August 10th. Canaccord Genuity assumed coverage on NantHealth in a report on Monday, June 27th. They set a “buy” rating and a $17.00 price objective on the stock. Jefferies Group assumed coverage on NantHealth in a research report on Monday, June 27th. They set a “buy” rating on the stock. Finally, Cowen and Company assumed coverage on NantHealth in a research report on Monday, June 27th. They set an “outperform” rating and a $19.00 price target on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. NantHealth has an average rating of “Buy” and a consensus price target of $18.00.
NantHealth (NYSE:NH) opened at 12.84 on Wednesday. The stock’s 50 day moving average price is $13.20 and its 200-day moving average price is $12.70. The firm’s market capitalization is $1.56 billion. NantHealth has a 12 month low of $9.79 and a 12 month high of $16.63.
NantHealth (NYSE:NH) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.26. The firm had revenue of $31.50 million for the quarter, compared to analysts’ expectations of $23.55 million. NantHealth’s revenue for the quarter was up 166.9% on a year-over-year basis. Equities analysts anticipate that NantHealth will post ($0.59) EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the company. Wildcat Capital Management LLC acquired a new stake in shares of NantHealth during the second quarter worth $3,008,000. Jefferies Group LLC acquired a new stake in shares of NantHealth during the second quarter worth $6,943,000. Blackstone Group L.P. acquired a new stake in shares of NantHealth during the second quarter worth $7,463,000. Finally, FMR LLC acquired a new stake in shares of NantHealth during the second quarter worth $11,250,000.
NantHealth, Inc, formerly Nant Health, LLC, is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.